According to a further analysis based on the type of ADT, the use of GnRH agonists had a high risk of hematological disorders (aHR = 2.75; 95% CI = 2.13–3.53), followed by oral antiandrogens (aHR = 1.79; 95% CI = 1.45–2.22). The gene discussed is GNRH1; the disease is hematologic disorder.